Compare BCG & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | SNTI |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | 150 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7M | 29.8M |
| IPO Year | N/A | 2021 |
| Metric | BCG | SNTI |
|---|---|---|
| Price | $1.48 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 27.4K | ★ 167.7K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.36 | $0.77 |
| 52 Week High | $3.44 | $2.88 |
| Indicator | BCG | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 49.05 |
| Support Level | $1.52 | $0.87 |
| Resistance Level | $2.49 | $1.03 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 20.01 | 41.25 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).